Which has grown faster, SGRY or XERS?

Over the past five years, XERS grew revenue faster — SGRY at a 9.90% CAGR versus XERS at 58.33%.

How have SGRY and XERS total returns compared?

Over the past 5 years, SGRY delivered -20.85% and XERS delivered 33.72% annualized total return. Past performance doesn't predict future results.

Surgery Partners, Inc. (SGRY) vs Xeris Biopharma Holdings, Inc. (XERS)

A side-by-side comparison of Surgery Partners, Inc. and Xeris Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

SGRY

Surgery Partners, Inc.

$1.77B

$13.50HealthcareDelayed quote: Oct 6, 2026, 2:55 PM EDT

XERS

Xeris Biopharma Holdings, Inc.

$1.73B

$10.05HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

Total return — SGRY vs XERS

growth of $100 · dividends reinvested · last 8y

SGRY -14.0% (-1.9%/yr)XERS -49.9% (-8.3%/yr)SGRY compounded faster over this window

SGRY XERS

SGRY vs XERS: by the numbers

•SGRY is the larger company ($1.77B vs $1.73B market cap).
•Both run net losses; SGRY's is the smaller (-2.63% vs -5.12% net margin).
•XERS grew revenue faster over the past five years (58.33% vs 9.90% CAGR).

Metrics side by side

Valuation

Metric	SGRY	XERS
Forward P/E	33.16	N/A
P/S ratio	0.52	5.17
P/B ratio	1.06	N/A
EV / EBITDA	9.64	38.76
FCF yield	10.63%	3.19%

Profitability

Metric	SGRY	XERS
Gross margin	21.37%	83.34%
Operating margin	11.89%	10.91%
Net margin	-2.63%	-5.12%
ROE	-5.30%	N/A
ROIC	4.23%	12.79%

Growth (annualized)

Metric	SGRY	XERS
Revenue CAGR (5Y)	9.90%	58.33%
FCF CAGR (5Y)	-0.84%	N/A
Total return CAGR (5Y)	-20.85%	33.72%

Frequently asked

Which has grown faster, SGRY or XERS?: Over the past five years, XERS grew revenue faster — SGRY at a 9.90% CAGR versus XERS at 58.33%.
How have SGRY and XERS total returns compared?: Over the past 5 years, SGRY delivered -20.85% and XERS delivered 33.72% annualized total return. Past performance doesn't predict future results.

Go deeper

Full SGRY analysis Full XERS analysis Interactive comparison tool

Dig into the metrics

Surgery Partners ROE Xeris Biopharma ROE Surgery Partners operating margin Xeris Biopharma operating margin Surgery Partners revenue growth Xeris Biopharma revenue growth Surgery Partners free cash flow Xeris Biopharma free cash flow

Surgery Partners & Xeris Biopharma appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.